Lemoxol

Ceftazidime, the active ingredient in Lemoxol, is a third‑generation cephalosporin presented as a parenteral solution for intramuscular and intravenous use. It treats severe Gram‑negative infections, including those caused by Pseudomonas aeruginosa, in hospitalized patients.

GNH USA supplies Lemoxol as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

Ceftazidime is indicated for infections caused by susceptible Gram‑negative bacteria, particularly in hospital‑acquired settings.

- Severe Gram‑negative infections: provides bactericidal activity to eradicate the pathogen. - Pseudomonas aeruginosa infections: effective against this resistant organism in systemic disease. - Nosocomial pneumonia: treats ventilator‑associated and other hospital‑acquired pneumonias. - Complicated urinary tract infections: clears infection when oral agents are insufficient. - Intra‑abdominal infections: used for peritonitis and related intra‑abdominal sepsis.

Ceftazidime may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Diarrhea: mild to moderate loose stools. - Nausea: occasional feeling of queasiness. - Rash: transient skin erythema. - Injection site pain: discomfort at the administration site.

Serious or Rare Side Effects: - Anaphylaxis: severe allergic reaction requiring immediate medical attention. - Stevens‑Johnson syndrome: rare but serious skin and mucous membrane disorder. - Clostridioides difficile‑associated colitis: severe intestinal inflammation. - Seizures: neurologic events, especially in patients with renal impairment.

Before using Lemoxol, consider the following safety measures.

- Renal function: assess kidney function and adjust dose in impairment. - Hepatic function: monitor liver enzymes during prolonged therapy. - Allergy history: avoid in patients with known cephalosporin or penicillin hypersensitivity. - Superinfection risk: watch for fungal or secondary bacterial overgrowth. - Pregnancy: category B; use only when benefit outweighs potential risk. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze.

Ceftazidime can interact with other medicines, altering efficacy or safety.

Major Interactions (Avoid): - Aminoglycosides: combined nephrotoxicity may increase renal damage. - Probenecid: reduces renal clearance, raising ceftazidime plasma levels. - Lithium: may increase lithium concentrations, risking toxicity.

Moderate Interactions (Monitor Closely): - Loop diuretics: monitor renal function and electrolytes. - NSAIDs: may enhance renal adverse effects. - Oral contraceptives: possible reduction in contraceptive effectiveness.